Ultima Genomics Expands Global Access to High-Quality, Low-Cost DNA Sequencing on the UG 100™ Sequencing Platform Through Partnerships With Multiple Premier Genomic Services Providers

Ultima Genomics, Inc., developer of the UG100™ next-generation sequencing (NGS) platform, announced expanded global access to high-quality, low-cost DNA sequencing with the addition of multiple new partnerships with leading genomic services providers. This global network of well-known service providers will offer industry-leading DNA sequencing services utilizing the UG 100 in support of single cell sequencing, spatial transcriptomics, proteomics, whole genome sequencing, and other applications. The world-class organizations announced today include Broad Clinical Labs, Eurofins, Novogene, Psomagen, and Ontario Institute of Cancer Research. These new partners join existing Ultima Genomics service provider partners Macrogen, Inocras, and the University of Minnesota Genomics Center.

"Ultima Genomics' unique sequencing platform architecture supports a range of genomics applications by providing cost-effective sequencing at unprecedented scale," said Jay Therrien, PhD, Chief Commercial Officer of Ultima Genomics. "We are excited to partner with these distinguished institutions to broaden access to the UG 100 to deliver maximum impact to researchers around the world."

Ultima's growing community of service providers includes diverse institutions such as leading academic centers, clinical labs, and commercial service providers. With this expansion, low-cost sequencing on the UG 100 sequencing platform will now be available through service providers in Asia-Pacific, EMEA and the Americas. Collectively, these partnerships are aimed at accelerating breakthroughs in fields such as AI/ML-enabled drug discovery and omics research by enabling access to sequencing at lower cost and larger scale.